Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area pi3k akt signaling pdk 1'

Search results for: 'research area pi3k akt signaling pdk 1'

9 Items

per page
  1. Everolimus (RAD001)
    A8169 Everolimus (RAD001)
     8 Citation
    Target: mTOR
    Summary: MTOR inhibitor
      ≥47.91 mg/mL
  2. PP 1
    A8215 PP 1
    Target: Src|EGFR|JAK|ZAP-70
    Summary: Src family tyrosine kinase inhibitor
  3. BYL-719
    A8346 BYL-719
     1 Citation
    Target: PI3K
    Summary: Selective PI3Kα inhibitor
      ≥22.07 mg/mL
  4. MK-2206 dihydrochloride
    A3010 MK-2206 dihydrochloride
     21 Citation
    Target: Akt
    Summary: Akt1/2/3 inhibitor
      insoluble in EtOH; ≥12.01 mg/mL
  5. WYE-125132 (WYE-132)
    B1642 WYE-125132 (WYE-132)
    Target: mTOR
    Summary: ATP-competitive mTOR inhibitor, highly potent
      insoluble in EtOH; insoluble in H2O; ≥13 mg/mL
  6. Motesanib
    A3632 Motesanib
    Target: VEGFR
    Summary: Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit
      ≥42 mg/mL
  7. Epirubicin HCl
    A2451 Epirubicin HCl
    Target: Topoisomerases
    Summary: Antibiotic antitumor agent
      ≥29.00 mg/mL
  8. Cediranib (AZD217)
    A1882 Cediranib (AZD217)
    Target: VEGFR
    Summary: VEGFR inhibitor receptor,highly potent
      ≥22.52 mg/mL
  9. Indoximod (NLG-8189)
    B4900 Indoximod (NLG-8189)
    Summary: Indoleamine 2,3-dioxygenase (IDO) pathway inhibitor
      insoluble in DMSO; insoluble in EtOH; ≥1.12 mg/mL

9 Items

per page
Shop By
Now Shopping by
  1. Reported Experiments Cell Experiments Remove This Item
  2. Related Disease Lung Cancer Remove This Item
Clear All
Shopping Options